ANI Pharmaceuticals
ANIP
71.93
+0.41
+0.57%
ANI Pharmaceuticals
US · ANIP
#2919 by market cap
Listed 1970
71.93
+0.41
+0.57%
Live - 5344 symbols - heartbeat 131s ago
· 2026-10-08 08:07
Pre-market
71.99
+0.08%
After-hours
72.15
+0.31%
- Market cap
- 1.65B
- P/E (TTM)i
- 15.67
- P/Bi
- 2.77
- EPSi
- 3.32
- Div yieldi
- 0.00%
- 52W posi
- 9%
Reader sentiment
Are you bullish or bearish on ANIP?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Mixed / stable
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 117.58% +0.03pp
- Institutions
- 365 +1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund80.29%
Hedge Fund17.17%
Public Company8.55%
Individual/Insider6.18%
VC/PE Fund4.73%
Private Company3.85%
Government Pension Fund2.83%
Top holders as of 2026-06-30
BlackRock
13.81% · 2.96M sh
MVP Capital Partners
4.73% · 1.01M sh
Vanguard Capital Management, LLC
4.53% · 971.81K sh
Soleus Capital Management, L.P.
4.05% · 867.76K sh
State Street Global Advisors
3.88% · 831.65K sh
Tang Capital Management, LLC
3.30% · 707.50K sh
Dimensional Fund Advisors
2.91% · 623.46K sh
American Century Investment Management
2.68% · 574.47K sh
Arrowstreet Capital, Limited Partnership
2.62% · 562.02K sh
Global Alpha Capital Management Ltd.
2.60% · 558.00K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 6 buys · 44 sells
| Name | Role | Stake |
|---|---|---|
| Nikhil Lalwani | Chief Executive Officer | 1.58% |
| Chad Gassert | Senior Vice President of Corporate Development & Strategy | 1.09% |
| Stephen Carey | Chief Financial Officer | 0.79% |
| Muthusamy Shanmugam | Head of R&D, COO of Novitium Operations & Director | 0.39% |
| Ori Gutwerg | Senior Vice President of Generics | 0.35% |
| Meredith Cook | Senior Vice President | 0.34% |
| Christopher Mutz | Head of Rare Disease | 0.29% |
| Krista Davis | Chief Human Resources Officer | 0.24% |
| Thomas Haughey | Independent Director | 0.18% |
| Patrick Walsh | Chairperson | 0.18% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-28 | Stephen Carey | Chief Financial Officer | Automatic Disposition | -2,850 | $73.00 |
| 2026-09-14 | Nikhil Lalwani | Chief Executive Officer | Automatic Disposition | -5,400 | $71.00 |
| 2026-09-13 | Meredith Cook | Senior Vice President | Automatic Disposition | -500 | $70.79 |
| 2026-09-10 | Jeanne Thoma | Independent Director | Automatic Disposition | -1,000 | $71.53 |
| 2026-08-30 | Stephen Carey | Chief Financial Officer | Automatic Disposition | -2,850 | $72.80 |
| 2026-08-24 | Nikhil Lalwani | Chief Executive Officer | Automatic Disposition | -5,400 | $74.30 |
| 2026-08-18 | Henry Gosebruch | Director | Other Acquisition | +6,662 | -- |
| 2026-08-12 | Meredith Cook | Senior Vice President | Automatic Disposition | -500 | $75.48 |
| 2026-08-09 | Ori Gutwerg | Senior Vice President of Generics | Open Market Disposition | -3,162 | $77.00 |
| 2026-07-28 | Stephen Carey | Chief Financial Officer | Automatic Disposition | -2,850 | $81.36 |
| 2026-07-17 | Meredith Cook | Senior Vice President | Sale to Issuer | -2,466 | $79.20 |
| 2026-07-12 | Meredith Cook | Senior Vice President | Automatic Disposition | -500 | $81.84 |
| 2026-07-06 | Patrick Walsh | Chairperson | Intent to Sell (Form 144) | -4,336 | $86.19 |
| 2026-07-01 | Stephen Carey | Chief Financial Officer | Derivative Exercise and Sale | -3,313 | $49.51–86.00 |
| 2026-06-28 | Stephen Carey | Chief Financial Officer | Automatic Disposition | -2,850 | $84.12 |
| 2026-06-11 | Meredith Cook | Senior Vice President | Automatic Disposition | -500 | $82.03 |
| 2026-06-07 | Thomas Haughey | Independent Director | Automatic Disposition | -2,000 | $80.88 |
| 2026-06-04 | Stephen Carey | Chief Financial Officer | Derivative Exercise and Sale | -3,312 | $49.51–80.00 |
| 2026-05-20 | Antonio Pera | Independent Director | Other Acquisition | +4,357 | -- |
| 2026-05-20 | Thomas Haughey | Independent Director | Other Acquisition | +4,357 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:07:21 · For reference only, not investment advice and not tailored to your situation.